Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 5;225(1):116-120.
doi: 10.1093/infdis/jiab336.

HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection

Jade Ghosn  1 , Lambert Assoumou  2 , Caroline Lascoux-Combe  3 , Gilles Peytavin  4 , Karine Amat  5 , Audrey Gabassi  6 , Minh P Le  4 , Robert Nzalakanda  2 , Nadia Valin  7 , Roland Landman  1 , Marie-Laure Chaix  6 , Constance Delaugerre  6
Affiliations

HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection

Jade Ghosn et al. J Infect Dis. .

Abstract

We compared the proportion of participants achieving first undetectable HIV-1 RNA (VL) in seminal plasma (SP) and blood plasma (BP) in 19 men starting dolutegravir-based regimen at primary HIV infection. At baseline, median VL was 6.5 (interquartile range [IQR], 5.6-7.9) and 4.5 (IQR, 3.5-5.0) log10 copies/mL in BP and SP, respectively. Between baseline and week 48, significantly higher proportion of participants achieved first VL below limit of quantification in SP (93.0%) than in BP (84.2%; P = .008). Time to first undetectable VL was 8 weeks in SP (95% confidence interval [CI], 5.6-10.4) and 24 weeks in BP (95% CI, 14.1-33.9).

Keywords: HIV-1; dolutegravir; drug concentration; primary HIV infection; seminal plasma.

PubMed Disclaimer

Publication types